Wyndly

Wyndly (https://www.wyndly.com) fixes allergies by training patients' bodies to ignore their allergy triggers. Frustrated allergy suffers come to us when they no longer want to deal with pills and sprays. We diagnose the patient’s unique allergy profile and create a personalized treatment plan to give the patient lifelong allergy relief. Specifically, Wyndly is increasing access to sublingual immunotherapy (SLIT) for allergy care. For our patients, we're combining the convenience of telehealth and direct-to-consumer care with an exceptional patient experience that never loses the context of care.

Wyndly represents an opportunity to change allergy care forever. With 60 million Americans suffering from allergies today, and with this number doubling over the coming years, there's simply an incredible need for the convenient care Wyndly provides.

You can read more about us in Techcrunch.

The Wyndly Model

At Wyndly, we believe that better connections lead to better care, and we’re committed to making both happen at every step of the patient journey. Our allergy practice allows our patients to work with expert providers to develop personalized treatment plans for long-term allergy relief using clinically proven therapies. From a patient’s initial consultation to their final treatment delivery, we want the Wyndly experience to be a breath of fresh air for allergy sufferers – truly effective allergy relief, simply and efficiently delivered.

Once we've conquered allergies, we're transforming the care model for every chronic condition. While transactional care for purchasing pills has flourished in telehealth, no one has gone after chronic care. Patients with chronic conditions are shuffled between providers, insurance, and more -- and they never feel heard. These patients deserve better, and we're going to give it to them. Wyndly is starting with allergies, but we'll expand into asthma, sleep apnea, and other conditions in the near future.

Our values

Compassion: We approach all our patients and partners with an open mind and a genuine desire to be of service.

Focus: We do a few things very well, and are always clear about our boundaries and direction of travel.

Courage: We embrace ambiguity and discomfort because we know that’s how we grow.

Progress: We make something better every single day.

*It boils down to empathy and forward momentum in everything we do.*

The team

Wyndly is proudly backed by Y Combinator and a leading group of angel investors and VCs. The founders are Dr. Manan Shah (Chief Medical Officer), an ear-nose-and-throat surgeon who’s a leading practitioner of telehealth in his specialty, and his cousin Aakash Shah (CEO), who led growth engineering at SparkGift (acquired by Stockpile in 2016) and Parse.ly (acquired by Automattic in 2021).

High-Level Overview

Wyndly is a healthcare company that provides personalized allergy treatment through telehealth, focusing on sublingual immunotherapy (SLIT) to retrain patients' immune systems to tolerate their allergy triggers. It serves millions of allergy sufferers who seek a convenient, effective alternative to traditional allergy medications and in-clinic allergy shots. Wyndly’s product includes an at-home allergy test kit, followed by a doctor-led personalized treatment plan delivered entirely remotely, making allergy care accessible and convenient. The company addresses the root cause of allergies rather than just managing symptoms, offering potential lifelong relief and reducing dependence on pills and sprays[1][2][4][5].

Origin Story

Wyndly was co-founded by Aakash and Manan Shah, a board-certified ENT and allergist with extensive experience treating allergies. The idea emerged during the COVID-19 pandemic when Manan realized patients preferred curing allergies from home rather than frequent clinic visits. This insight led to developing a telehealth platform that combines at-home testing with personalized immunotherapy treatment plans. Early traction came from successfully treating thousands of patients remotely, demonstrating the viability and demand for convenient, high-quality allergy care[2][4].

Core Differentiators

• Personalized Treatment: Uses at-home allergy testing to identify individual allergens and create tailored immunotherapy plans.
• Doctor-Led Care: Consultations are conducted directly with board-certified doctors, not nurses, enhancing trust and treatment quality.
• Convenience: Entirely remote process—testing, consultation, and treatment—eliminates the need for frequent clinic visits.
• Clinically Proven Therapy: Employs FDA-approved SLIT tablets and allergy drops, a scientifically validated alternative to allergy shots.
• Money-Back Guarantee: Offers a refund if patients do not see relief within three months, underscoring confidence in effectiveness.
• LegitScript Certification: Provides additional assurance of safety and legitimacy in telehealth allergy treatment[3][4][5][7].

Role in the Broader Tech Landscape

Wyndly rides the growing trend of telemedicine and personalized healthcare, leveraging digital tools to disrupt traditional allergy treatment. The timing is critical as allergy prevalence rises due to environmental factors like increased pollen and pollution, while access to allergists remains limited (one allergist per 17,000 sufferers). Wyndly’s model addresses this gap by democratizing access to effective allergy immunotherapy, reducing healthcare system burdens, and improving patient quality of life. Its approach exemplifies how technology can transform chronic disease management by combining convenience, personalization, and clinical rigor[1][2][4].

Quick Take & Future Outlook

Wyndly is well-positioned to expand as allergy rates climb and demand for telehealth solutions grows. Future trends shaping its journey include broader insurance acceptance, geographic expansion of telehealth services, and potential integration with other digital health platforms. As awareness of allergy immunotherapy increases, Wyndly’s influence could extend beyond allergy care to inspire similar models for other chronic conditions. Continued innovation in personalized medicine and patient experience will be key to sustaining growth and impact, fulfilling its mission that life truly is better without allergies[2][4][5].